EyeTechCare has raised US$9 million
June 2010 — EyeTechCare has raised US$9 million, with funds provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders.
Founded in 2008 and based in Rillieux-la-Pape, near Lyon, France, EyeTechCare provides innovative medical non-invasive devices to permanently cure glaucoma, the first cause of blindness in developed countries.
The funds raised in this second financing will be used to complete the first clinical trial on humans, as well as establish the manufacturing facilities and the sales and marketing force required for this first product. The market launch is scheduled for early 2011.
Our role in the transaction
Oaklins’ team in France reviewed the strategy with the board and organized a fundraising with specialized venture funds.
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more